Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. | Once ...

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

Three months ago, in its third-quarter report, Madrigal pointed out that it achieved a key goal early by gaining 80% coverage ...

Zevra used the awareness day to roll out the “Learn NPC, Read Between the Signs” disease awareness campaign. The biotech won ...

Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd brought ...

As Merck & Co. hunts for an ideal spot to set up a new commercial facility, Delaware is looking to bolster its odds with a ...

Get ready to see more of Henry Winkler on TV talking about geographic atrophy (GA). | During a quarterly conference call, as ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, ...

Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...

Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...

More than a decade after earning FDA approval for Xiaflex as a nonsurgical treatment option for Dupuytren’s contracture, Endo ...

For Zevra Therapeutics, last year’s approval of the rare lysosomal storage disorder drug Miplyffa appears to be the gift that ...